Summit Therapeutics Share Discussion Threads

[waterloo01] 11/8/2021 15:27

Interesting. Combining the two. Does that mean they are now recruited?

[chrisatrdg] 18/5/2021 20:24

NASDAQ currently 15.33% up at $7.90 clearly markets like Quarterly accounts cash to Qtr 4 2022 & todays RNS.

[chrisatrdg] 18/5/2021 13:26

Todays RNS:

Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738̶1;), for development in the fight against multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. Simultaneously, Summit has received an award from CARB-X to progress this candidate through preclinical development and Phase 1a clinical trials. The award commits initial funding of up to $4.1 million, with the possibility of up to another $3.7 million based on the achievement of future milestones.

SMT-738 is the first of a novel class of precision antibiotics with a new mechanism of action that acts via the bacterial target, LolCDE. SMT-738 has the potential to treat multidrug resistant infections caused by a large family of pathogenic Gram-negative bacteria, the Enterobacteriaceae, that include serious human pathogens such as Escherichia coli and Klebsiella pneumoniae. Combining a novel antibiotic class (SMT-738) with a clinically unexploited target (LolCDE) mitigates the risk of pre-existing resistance, potentially allowing for the effective treatment of Enterobacteriaceae-caused infections that currently have very limited and failing treatment options due to resistance to existing antibiotic classes.

“Our mission at Summit is to create patient- and societal-friendly medicinal therapies that improve the quality and duration of patients’ lives, while resolving serious unmet needs,” said Robert W. Duggan, Executive Chairman and Chief Executive Officer of Summit. “SMT-738 has the potential to save the lives of patients with as yet untreatable infections through a novel drug class with a low propensity for resistance development. We are excited and optimistic to take on the real challenge of antibiotic resistance and are grateful to CARB-X for partnering with us in support of this important mission.”

SMT-738 was discovered using Summit’s proprietary technology, our Discuva Platform, as a part of the DDS-04 series, and we retain worldwide clinical development and commercial rights to the compound. We expect to begin Phase 1 studies in 2023.

“With the growing threat of antibiotic resistance, particularly with respect to CRE infections, SMT-738 is clearly differentiated from all agents, including the beta-lactamase inhibitors, that are currently used to treat such infections,” adds David Powell, Ph.D., Summit’s Chief Scientific Officer. “By leveraging the transposon libraries of bacteria within our Discuva Platform, we have identified the target to be the clinically unexploited LolCDE complex, an essential lipid transport system in Gram-negative bacteria. SMT-738 has potent in vitro activity against clinical CRE isolates including difficult to treat metallo-beta-lactamase carrying strains encoding the New Delhi Metallo-beta-lactamase (NDM). Having encountered no existing resistance in clinical isolates to the novel chemistry of SMT-738, the ability of our drug molecule to reset the clock against growing resistance is critical in our collective fight against these pathogens causing an urgent public health threat.”

Carbapenem-resistant Enterobacteriaceae are considered an Urgent Threat by the US Centers for Disease Control and Prevention (CDC) and a Critical Priority by the World Health Organization (WHO) for which new treatments are urgently needed.

[waterloo01] 18/5/2021 07:53

No idea why though. Recruitment has slowed and it could take between 7 (at 100 per Q) and 14 (at 50 per Q) quarters to complete. That's between 2-3 years!

[chrisatrdg] 17/5/2021 20:33

The successful recent fund raise todays reported first quarters figures have clearly ignited the share price which is currently some 35% up.

[waterloo01] 02/5/2021 17:27

O/T now but of some interest.

Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing

Abstract
Duchenne muscular dystrophy (DMD) is a fatal muscle disease caused by the lack of dystrophin, which maintains muscle membrane integrity. We used an adenine base editor (ABE) to modify splice donor sites of the dystrophin gene, causing skipping of a common DMD deletion mutation of exon 51 (∆Ex51) in cardiomyocytes derived from human induced pluripotent stem cells, restoring dystrophin expression. Prime editing was also capable of reframing the dystrophin open reading frame in these cardiomyocytes. Intramuscular injection of ∆Ex51 mice with adeno-associated virus serotype-9 encoding ABE components as a split-intein trans-splicing system allowed gene editing and disease correction in vivo. Our findings demonstrate the effectiveness of nucleotide editing for the correction of diverse DMD mutations with minimal modification of the genome, although improved delivery methods will be required before these strategies can be used to sufficiently edit the genome in patients with DMD.

[chrisatrdg] 28/2/2021 21:09

Interesting to see the increased interest in Summit as shown by the current Institutional Holdings currently scheduled.

[chrisatrdg] 25/2/2021 12:37

Four more postings on share options dated 23rd Feb 2021

[cautiousmoney] 18/2/2021 12:50

off topic i know but WELL WORTH a read !!

hxxps://www.westonaprice.org/podcast/246-vaccine-facts-few-know-about/

[kirk 6] 16/2/2021 16:53

I have fully sold and unwound a large position here, much easier to do it in the NASDAQ as well. Made about 600,000 quid so not done too badly out of summit Therapeutics

[kirk 6] 16/2/2021 16:52

It's quite funny looking back over the past year and a few posters on here would desperately upset about the cancellation of the AIM listing and the moving over to the NASDAQ. I wish every single UK share I had would cancel the listing and move to the NASDAQ. The amount of hype over on the NASDAQ and the US market is incredible. I have written to the board of directors of most of the companies stocks I own to recommend they cancel and move to the NASDAQ or US markets.

[chrisatrdg] 16/2/2021 16:50

I note from todays SEC filing that Polar Capital have increased their holding from 0 (reported 30/09/20) to 5,800,000 (7.05%)(reported 16/02/21)

In addition to the above Polar Capital LLP hold 5,000,000 as at 30/09/20 adding at that point 500,000 & still holding today.



Edit: Shows Polar Capital still showing interest in Summit & may explain todays share price increase.

[chrisatrdg] 10/2/2021 16:15

Hi All - I had my e-mail reply yesterday from Summit in the US & the update on trials will be part of the Annual Report & Accounts 31.12.20 to be published within 75 days of the year end - see extract below.

'As we have disclosed in our previous quarterly Earnings Releases (via both Form 8-K on the US SEC website (www.sec.gov) and a Press Release), we update stakeholders as to the status of our trials on a quarterly-basis, including enrollment progress or other indications with respect to our progression. Our annual report on Form 10-K and associated Earnings Releases via Form 8-K are filed within 75 days of our fiscal year end (December 31, 2020), and we expect they will be made available in that timeframe.'

[football] 09/2/2021 14:14

Pre-Market Trades
Pre-Market Time (ET) Pre-Market Price Pre-Market Share Volume
08:54:32 $10.58 5
08:47:09 $11.80 178
08:28:28 $11.75 30
08:00:07 $12.00 2
07:00:42 $11.09 1

[chrisatrdg] 09/2/2021 13:15

Another posting after the above:

Chrisatrdg
Posts: 2,155
Price: 0.00
Strong Buy
RE: Next stop?Today 13:04
On my ii account at the moment the Bid is $11.19 & the Ask $8.96 all very scary.

[chrisatrdg] 09/2/2021 13:14

Following the above I posted:

Chrisatrdg
Posts: 2,155
Price: 0.00
Strong Buy
RE: Next stop?Today 13:01
Hi EP - I de-risked in January leaving 1,400 shares in my non-ISA account & over the last 3-4 years have Sold some 75% of my shares & over that time achieved 'Break Even'.My 1,400 shares are now worth £11,374 (up 122.30%) & cannot Sell because of CGT limits.
I realised my error in January & bought back in a few days after 1,445 shares now worth £11,739 (up 78.93%) in less than a month but are in a Stock ISA.
I can understand your dilemma EP as I have been in the same position on two occasions & did not Sell at great cost to me.
The sensible thing to do for me is to Sell today my ISA shares & pocket the money but who would have thought the shares would have gone up 24.89% yesterday & will this be repeated today.
I remember talking to the Chief Scientific officer at a Summit AGM 2 years ago & he said that if Summit are successful with C-Diff the share price increase would be significant I guess double or treble & likely more if Summit go to market is my thinking now.
I have e-mailed Summit this week on the issue of the trials & I am awaiting an answer but if the current share price is a blip down it will go back to where we started.
I will await the opening bell with finger at the ready & based on my previous experiences should Sell (Third time lucky).
Regards to all.

[chrisatrdg] 09/2/2021 13:13

Following the above EP posted:

English_Parisien
Posts: 773
Price: 0.00
No Opinion
Next stop?Today 07:02
I am nearly at that fateful inflexion point I find myself at in June 2018 when this all when wrong ... what to do, what to do?!

Reading online, Phase III results aren’t expected before Sept ‘21.

So what then is driving this??
Aforementioned GameStop effect?
People catching onto the Duggan (read: Midas) touch?

I am keen to avoid itchy finger and derisk when this just might be getting to the “interesting” part ... but have also seen this too many times before ...

GLA
- EP

[chrisatrdg] 09/2/2021 13:11

Below was posted early this morning - do we have a bubble problem:

JohnLaw Premium Member
Posts: 625
Price: 0.00
Strong Buy
RE: Wow....Today 04:57
There is a growing following on Stocktwits with c 1600 followers. Some of them are classing this with Gamestop and AMC..... Been here for years but getting ready to jump.

Edit: Try reading the link & ask yourself Sell or Buy ??????

[artrade] 08/2/2021 19:29

@ cautiousmoney. Not sure if you were joking but I probably worded it obscurely but I am commiserating with the boys. I vividly remember the day the announcement was made about the failed Trials. I had some of my patients enrolled at an earlier trial stage.. And of course we all lost a lot of money.

They way it was dealt with by Summit management was really the last straw as only a few weeks earlier they had said how everything was going well. This was of course not the first, second or fifth time they said one thing but actually meant another to muddy the waters of punters.

I think a lot of pumping is going on now as how can this company be worth 750 Million Dollars with the small portfolio. Reddit effect maybe !

I will be reducing and maybe completely selling out my residual holdings.

[chrisatrdg] 08/2/2021 17:26

Hi wildbunch - It is a double blinded trial so there is no way news could have escaped as there is no details of how the trials are doing.
I can only guess that the share price rise is caused by recent updates on the trial website as I have previously posted.
I am holding my reduced investment & finally going for broke although my recent Buy backs are in a Stock ISA.
My fear is that when they produce their Annual Report & Accounts they will detail the current take up on the trials previously held back because of Covid.
I have e-mailed the states today to try & get a handle on the trials progress.
As with all shares people Buy in when they see continual share price increases.
Currently we are at $11.23 up 25.26%.

[wildbunch] 08/2/2021 17:07

Can news have got out from trial about efficacy?

[waterloo01] 08/2/2021 16:50

Well done, a bit painful as don't hold any! Grr.

[cautiousmoney] 08/2/2021 16:48

lol up 35%
now $12.16

[football] 08/2/2021 16:47

You mean $12